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ABSTRACT Invasive nontyphoidal Salmonella (iNTS) infections are commonly associ-
ated with Plasmodium falciparum infections, but the immunologic basis for this link-
age is poorly understood. We hypothesized that P. falciparum infection compromises
the humoral and cellular immunity of the host to NTS, which increases the suscepti-
bility of the host to iNTS infection. We prospectively recruited children aged be-
tween 6 and 60 months at a Community Health Centre in Blantyre, Malawi, and allo-
cated them to the following groups; febrile with uncomplicated malaria, febrile
malaria negative, and nonfebrile malaria negative. Levels of Salmonella enterica sero-
var Typhimurium-speciﬁc serum bactericidal activity (SBA) and whole-blood bacteri-
cidal activity (WBBA), complement C3 deposition, and neutrophil respiratory burst
activity (NRBA) were measured. Levels of SBA with respect to S. Typhimurium were
reduced in febrile P. falciparum-infected children (median, 0.20 log10 [interquartile
range {IQR}, 1.85, 0.32]) compared to nonfebrile malaria-negative children (median,
1.42 log10 [IQR, 2.0, 0.47], P  0.052). In relation to SBA, C3 deposition on S.
Typhimurium was signiﬁcantly reduced in febrile P. falciparum-infected children (me-
dian, 7.5% [IQR, 4.1, 15.0]) compared to nonfebrile malaria-negative children (me-
dian, 29% [IQR, 11.8, 48.0], P  0.048). WBBA with respect to S. Typhimurium was
signiﬁcantly reduced in febrile P. falciparum-infected children (median, 0.25 log10
[IQR, 0.73, 1.13], P  0.0001) compared to nonfebrile malaria-negative children
(median, 1.0 log10 [IQR, 1.68, 0.16]). In relation to WBBA, S. Typhimurium-
speciﬁc NRBA was reduced in febrile P. falciparum-infected children (median, 8.8%
[IQR, 3.7, 20], P  0.0001) compared to nonfebrile malaria-negative children (median,
40.5% [IQR, 33, 65.8]). P. falciparum infection impairs humoral and cellular immunity
to S. Typhimurium in children during malaria episodes, which may explain the in-
creased risk of iNTS observed in children from settings of malaria endemicity. The
mechanisms underlying humoral immunity impairment are incompletely understood
and should be explored further.
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Invasive nontyphoidal Salmonella (iNTS) infections, principally by Salmonella entericaserovar Typhimurium and S. enterica serovar Enteritidis, are estimated to cause over
2.1 million illnesses and 416,000 deaths per year (1). In settings of malaria endemicity,
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invasive NTS infections are commonly associated with current or convalescent episodes
of malaria, in particular, severe malarial anemia (2, 3). Other factors associated with
increased susceptibility to iNTS in children are immature immunity and malnutrition,
while HIV infection is the driving force for iNTS susceptibility in adults (4, 5). About 6.5%
of invasive bacterial infections (IBIs) occur in P. falciparum-infected children (6, 7);
however, in view of the low sensitivity of blood cultures, P. falciparum infection might
account for more than 50% of IBIs in children living in settings of malaria endemicity
(8). Often, children are diagnosed and treated for malaria while IBI is left unattended,
leading to poor health outcomes.
The association between malaria and iNTS was ﬁrst reported in the 1920s (9). Biggs
et al. recently reported that coinfections by iNTS and malaria were common in febrile
pediatric in-patients from an area of high malaria transmission compared to those from
an area of low malaria transmission in Tanzania (10). In contrast, S. Typhi bacteremia
was uncommon in febrile pediatric in-patients from an area of high malaria transmis-
sion (10). In addition, the association between iNTS and malaria is observed in seasonal
peaks during the rainy season (4, 5, 11, 12). However, the immunologic basis for
increased numbers of iNTS cases in settings of malaria endemicity is not fully under-
stood.
The link between NTS and malaria in humans and mice is extensively covered in the
reviews by Uche et al. (13) and Takem et al. (14). Phagocytes (including neutrophils and
monocytes) are key players in controlling rapid replicating NTS within the gut mucosa
and hence in preventing the spread of NTS to systemic organs (15). Studies in both
humans and mice have shown that P. falciparum-derived products such as hemozoin,
heme, and heme oxygenase-1 mediate the reduction in phagocytosis and oxidative
burst activities (16–18). Some studies have shown that during acute malaria, levels of
the proinﬂammatory cytokine interleukin-12 (IL-12) are reduced whereas levels of the
anti-inﬂammatory cytokine IL-10 are increased (19–22). The anti-inﬂammatory environ-
ment, coupled with reduced levels of phagocytosis and oxidative burst activities during
malaria, is thought to create a favorable setting for NTS replication within the gut
mucosa and bloodstream compartments. However, the role of humoral immunity to
NTS during P. falciparum infection has not been explored extensively, although its role
in nonmalarial children has been studied before (23–25).
Immunoglobulin G (IgG) antibodies to NTS targeting lipopolysaccharide (LPS) are
thought to confer some protection against NTS bacteremia in African children (23, 25,
26). Opsonizing anti-NTS LPS IgG antibodies mediate NTS killing in a cell-free manner
through the complement cascade membrane attack complex (MAC) and also facilitate
killing by phagocytes, which involves phagocytosis and respiratory burst-mediated
killing (24). We envisaged that exploring the role of humoral immunity to iNTS during
malaria will broaden our understanding of the association between iNTS and malaria
and augment the studies that were previously focused on cellular immunity. Therefore,
we examined cell-free bactericidal activities and cellular bactericidal activities against
NTS in a cohort of children with uncomplicated P. falciparum infections. We show that
during malaria, P. falciparum infection impairs serum bactericidal immunity to S.
Typhimurium via altered complement C3 deposition on S. Typhimurium in addition to
the impairment of the respiratory burst of phagocytes which was known before,
providing a comprehensive explanation for the increased susceptibility to iNTS seen in
children during malaria.
RESULTS
Transient loss of serum bactericidal immunity to S. Typhimurium during cur-
rent or convalescent P. falciparum infection. We have previously shown that acqui-
sition of serum bactericidal activity (SBA) with respect to S. Typhimurium correlates with
the decline in iNTS infections in childhood in individuals not infected with P. falciparum
(23, 25). Therefore, we ﬁrst examined SBA to determine whether SBA with respect to S.
Typhimurium is reduced in P. falciparum-infected children. We found that SBA with
respect to S. Typhimurium was reduced but did not reach statistical signiﬁcance
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difference in children with acute malaria (median, 0.20 log10 [interquartile range
{IQR}, 1.85, 0.32]) compared to nonfebrile malaria-negative children (median, 1.42
log10 [IQR, 2.0, 0.47], P  0.052) (Fig. 1A). SBA with respect to S. Typhimurium was
signiﬁcantly reduced in children with acute malaria (median, 0.20 log10 [IQR, 1.85,
0.32], P  0.0007) and at day 14 in convalescence (median, 0.49 log10 [IQR, 2.0,
0.49], P  0.0054) compared to febrile malaria-negative children (median, 1.85 log10
[IQR, 2.85, 1.24]) (Fig. 1A). SBA with respect to S. Typhimurium at 30 days in
convalescence (median, 1.85 log10 [IQR, 2.24, 0.06]) was similar to that seen with
febrile malaria-negative children (median, 1.85 log10 [IQR, 2.85, 1.24], P  0.43)
and nonfebrile malaria-negative children (median, 1.42 log10 [IQR, 2.0, 0.47], P 
0.39) (Fig. 1A). Furthermore, in a subset of children we found that 6/23 (26%) had robust
SBA with respect to S. Typhimurium (ability to kill S. Typhimurium by at least a 1.0
log10 change in S. Typhimurium CFU counts per milliliter) in the acute malaria phase
compared to 16/23 (69.5%) at day 30 in convalescence (Fig. 1B). We also found that of
16 children who lacked robust SBA with respect to S. Typhimurium in the acute malaria
phase, 10 (62.5%) attained robust SBA with respect to S. Typhimurium at day 30 in
convalescence.
We have previously shown that acquisition of SBA with respect to S. Typhimurium
correlates with age in healthy children (25). We found that acquisition of robust SBA
with respect to S. Typhimurium correlated with age development in febrile nonmalarial
children and in nonfebrile malaria-negative children (Spearman’s r  0.43 [P 
0.0037] and r  0.38 [P  0.0086], respectively) (Fig. 2A and B). Interestingly, we
observed that during acute P. falciparum infection, at day 14 and day 30 in convales-
cence, SBA with respect to S. Typhimurium did not kill S. Typhimurium at a level of at
least a 1 log10 change in S. Typhimurium CFU counts per milliliter in some older
children (24 months of age; those children were considered to have had serum results
showing immunity to S. Typhimurium [23]) and SBA with respect to S. Typhimurium
that poorly correlated with age (acute malaria Spearman’s r  0.23 [P  0.11]; day 14
r  0.15 [P  0.37]; day 30 Spearman’s r  0.16 [P  0.39]) (Fig. 2C to E).
SBA with respect to S. Typhimurium is mainly mediated by anti-S. Typhimurium IgG
antibodies targeting LPS (23, 25). Unexpectedly, we found that SBA with respect to S.
FIG 1 Transient loss of serum bactericidal immunity to S. Typhimurium during current and convalescent P. falciparum infection. Serum bactericidal
activity was reported as the log10 change in S. Typhimurium CFU counts per milliliter from the baseline, and this was plotted as indicated during
malaria and in controls. (A) Red bars represent the median, and statistical differences were determined by the Mann-Whitney U test. (B) Serum
bactericidal activity measurements for each subject during current and convalescent malaria are linked by solid gray lines.
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Typhimurium in nonfebrile malaria-negative children poorly correlated with anti-S.
Typhimurium LPS IgG antibody titers (Spearman’s r  0.038, P  0.81) whereas SBA in
febrile nonmalarial children correlated with anti-S. Typhimurium LPS IgG antibody titers
(Spearman’s r0.34, P 0.03) (Fig. 3A and B). Interestingly, we observed that during
acute malaria, SBA with respect to S. Typhimurium poorly correlated with anti-S.
Typhimurium LPS IgG antibody titers (Spearman’s r  0.19, P  0.20) whereas the
correlation of SBA with anti-S. Typhimurium LPS IgG antibody titers was superior at day
14 and day 30 in convalescence; however, this was statistically signiﬁcant only at day
14 (Spearman’s r  0.37 [P  0.04] and r  0.29 [P  0.15], respectively) (Fig. 3C to
E). These ﬁndings suggest that P. falciparum infection induced the transient loss of
serum bactericidal activity with respect to S. Typhimurium in P. falciparum-infected
children and that the effect was independent of age and acquired antibody immunity.
To explore this further, we randomly selected serum samples (n  10) from children
(24 months old) to examine levels of complement C3 and C5b-9 deposition during
malaria (Fig. 4). Interestingly, we found that C3 deposition on S. Typhimurium was
signiﬁcantly lower in febrile P. falciparum-infected children (median, 7.5% [IQR, 4.1,
15.0]) than in febrile malaria-negative children (median, 60% [IQR, 21.5, 71.5], P 0.003)
FIG 2 Relationship between serum bactericidal activity with respect to S. Typhimurium and age during malaria. Serum bactericidal
activity was reported as the log10 change in S. Typhimurium CFU counts per milliliter from the baseline, and this was plotted against
age in months as indicated in controls and during malaria. Spearman’s r correlation coefﬁcient and P values are reported.
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and nonfebrile malaria-negative children (median, 29% [IQR, 11.8, 48.0], P 0.048) (Fig.
4C and E). C3 deposition was also lower in febrile P. falciparum-infected children
(median, 7.5% [IQR, 4.1, 15.0]) than at day 30 of convalescence (median, 19% [IQR, 12.1,
58.8], P  0.027) and that the level was similar at day 14 in convalescence (median,
19.5% [IQR, 10.7, 28.7], P  0.113) (Fig. 4C and D).
C5b-9 deposition on S. Typhimurium was signiﬁcantly lower in febrile P. falciparum-
infected children (median, 21% [IQR, 9.6, 31.0]) than in febrile malaria-negative children
(median, 34% [IQR, 29, 74.5], P  0.012) but was not signiﬁcantly different from that
seen in nonfebrile malaria-negative children (median, 28% [IQR, 14.35, 40.8], P  0.57).
There were no signiﬁcant differences in C5b-9 deposition on S. Typhimurium in febrile
P. falciparum-infected children (median, 21% [IQR, 9.6, 31.0]) from the levels seen at day
14 in convalescence (median, 24% [IQR, 24.8, 46.5], P  0.084) and at day 30 in
convalescence (median, 38% [IQR, 29, 64], P 0.084) (Fig. 4E and F). Taken together, the
data suggest a transient increase in consumption of the C3 complement component
during acute malaria which rebounded to levels comparable to those seen with
nonmalarial children by day 14 of malaria convalescence.
FIG 3 Relationship between serum bactericidal activity with respect to S. Typhimurium (STm) and anti-IgG antibody targeting S.
Typhimurium LPS. Serum bactericidal activity with respect to S. Typhimurium was plotted for anti-IgG antibodies targeting S. Typhimurium
LPS in controls and during malaria as indicated. Spearman’s r correlation coefﬁcient and P values are reported.
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Serum is a prerequisite for blood cell killing of S. Typhimurium. S. Typhimurium
is a facultative intracellular organism that requires the action of both cellular immunity
and humoral immunity to be effectively controlled. We therefore examined if levels of
whole-blood killing of S. Typhimurium were also reduced during P. falciparum infection.
We found that whole-blood bactericidal activity (WBBA) with respect to S. Typhimurium
was reduced during malaria at the acute stage (median, 0.25 log10 [IQR, 0.73, 1.13],
P  0.0001), day 14 in convalescence (median, 0.51 log10 [IQR, 1.53, 0.57], P 
0.110), and day 30 in convalescence (median,0.19 log10 [IQR,0.96, 0.64], P 0.009)
and in febrile malaria-negative children (median, 0.18 log10 [IQR, 0.66, 0.87], P 
FIG 4 Reduced C3 deposition on S. Typhimurium during the acute phase of P. falciparum infection in children. Serum (n  10) was
randomly selected from donor children24 months of age during malaria and from controls. (A) Serum bactericidal activity was reported
as the log10 change in S. Typhimurium CFU counts per milliliter from the baseline, and this was plotted as indicated during malaria and
in controls. (B) Serum bactericidal activity and malaria were linked. (D and F) The proportions of C3 deposition (D) and C5b-9 deposition
(F) on S. Typhimurium measurements for each subject during current and convalescent malaria are linked by solid gray lines. Red bars
represent the median, and statistical differences were determined by the Wilcoxon signed-rank test and Mann-Whitney U test.
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0.004) compared to nonfebrile malaria-negative children (median, 1.0 log10 [IQR,
1.68, 0.16]) (Fig. 5A).
Humoral immunity enhances intracellular killing of S. Typhimurium (24). We ob-
served that washed-blood-cell bactericidal activity (WBCBA) with respect to S. Typhi-
murium during malaria was abrogated in febrile malaria-negative children and nonfe-
brile malaria-negative children under all washed-blood-cell conditions examined (Fig.
5A and B). To determine if serum-mediated immunity is required for efﬁcient washed-
blood-cell killing of S. Typhimurium, we examined the assay after S. Typhimurium was
opsonized with autologous serum, and we found that killing of S. Typhimurium was
partially restored (Fig. 5). We show that WBBA with respect to S. Typhimurium was reduced
during malaria and in febrile illness in children and that serum opsonization is essential for
cellular killing.
Reduced S. Typhimurium-speciﬁc neutrophil respiratory burst in malaria and
febrile nonmalarial children. To identify the speciﬁc bactericidal function that was
FIG 5 Reduced blood cell killing of S. Typhimurium (STm) in malarial and nonmalarial febrile children. Whole-blood (A), washed-blood (B), or
serum-opsonized washed-blood (C) bactericidal activity was reported as the log10 change in S. Typhimurium CFU counts per milliliter from the
baseline and plotted as indicated during malaria and in controls. Red bars represent the median, and statistical differences were determined by
the Mann-Whitney U test.
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altered in children with malaria and febrile illness, we examined neutrophil respiratory
burst activity (NRBA) as it is a key mechanism for intracellular pathogen killing. We
found that NRBA was signiﬁcantly reduced in children during acute malaria (median,
8.8% [IQR, 3.7, 20], P  0.0001) and also in febrile malaria-negative children (median,
9.4% [IQR, 4.4, 19.5], P  0.0001) compared to nonfebrile malaria-negative children
(median, 40.5% [IQR, 33, 65.8]) (Fig. 6). We observed that in P. falciparum-infected
children, there was a modest trend for improved respiratory burst at day 14 (median,
17% [IQR, 5.1, 31.5], P  0.135) and day 30 (median, 17% [IQR, 6.1, 32], P  0.042) in
convalescence compared to the acute malaria phase (median, 8.8% [IQR, 3.7, 20]) (Fig.
6B) but that there remained a signiﬁcant defect even at 1 month. This shows that both
malarial and nonmalarial febrile children have impaired NRBA with respect to S.
Typhimurium. The pattern over time was similar to that seen for whole-blood killing, in
keeping with the oxidative burst being a dominant mechanism for the observed
whole-blood bacterial killing.
DISCUSSION
This study extended our understanding of how P. falciparum infection compromises
phagocyte-dependent immunity to NTS in children (16–18) and provided an additional
explanation for the observed increased susceptibility of children to iNTS in settings of
malaria endemicity. Our report describes the transient loss of serum bactericidal
immunity to iNTS during current or convalescent P. falciparum infection in children. This
loss of serum bactericidal immunity was speciﬁc to children who were febrile from
malaria compared to other causes of fever. P. falciparum infection appears to compro-
mise serum bactericidal immunity to iNTS in older children, and the effect does not
correlate with preexisting IgG antibodies to S. Typhimurium LPS. This is likely caused by
FIG 6 Reduced S. Typhimurium-speciﬁc neutrophil respiratory burst activity in malarial and nonmalarial febrile children. (A) The
representative gating strategy for neutrophils using forward-scatter (FSC) and side-scatter (SSC) expression followed by neutrophil
respiratory burst activity plots in unstimulated or S. Typhimurium-stimulated cells is shown. (B) Percentages of S. Typhimurium-speciﬁc
neutrophil respiratory burst-positive cells during malaria and in controls were plotted as indicated. Red bars represent the median, and
statistical differences were determined by the Mann-Whitney U test.
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the increased consumption of the C3 complement component during P. falciparum
infection.
In this study, we demonstrated the transient loss of bactericidal humoral immunity
to S. Typhimurium in children with current or convalescent P. falciparum infection. The
loss in bactericidal SBA with respect to S. Typhimurium was independent of age and
anti-S. Typhimurium LPS IgG antibody titers during acute malaria and at day 14 of
convalescence, and robust SBA with respect to S. Typhimurium was restored after 30
days of convalescence. This was explored further by examining deposition of comple-
ment components on S. Typhimurium. Consistent with previous ﬁndings (27), we found
that the level of deposition of mainly the C3 complement component was transiently
reduced during the acute phase of P. falciparum infection and rebounded at days 14
and 30 in malaria convalescence to levels comparable to those seen with nonmalaria
controls. This is in keeping with the lack of robust SBA with respect to S. Typhimurium
seen during acute malaria in some children with high anti-S. Typhimurium LPS-IgG
antibody titers. Increased consumption of complement components, particularly C3,
during acute malaria as observed in the current study and other studies (27), which are
crucial for antibody dependent-complement killing of Gram-negative bacteria (23, 28),
may favor the proliferation of S. Typhimurium. We observed that at day 14 in malaria-
convalescent children, SBA with respect to S. Typhimurium remained poor despite
complement protein C3 on S. Typhimurium rebounding to normal levels, suggesting
that other factors may be involved in compromising serum bactericidal immunity
during malaria, and this needs to be investigated further. P. falciparum has also
developed complement killing escape strategies; it is possible that serum killing is
abrogated during malaria via P. falciparum recruitment of factor H protein which
prevents complement cascade activation via the C3b (29–31), ultimately blocking
complement-mediated NTS lysis. Furthermore, P. falciparum infection may compromise
humoral immunity to NTS via a reduction of the antibody opsonization capacity as
observed in some studies (32), as well as via defective complement cascade activation.
This observation suggests that in children in settings where exposure to NTS is frequent
and where malaria is highly endemic, humoral bactericidal immunity may be lost
during repeated malaria episodes, increasing overall susceptibility to iNTS by favoring
NTS proliferation and systemic infection.
We have shown that levels of WBBA with respect to S. Typhimurium are reduced in
both P. falciparum-infected and febrile malaria-negative children. Consistent with pre-
vious observations (24), our ﬁndings indicate that serum immunity plays a crucial role
in both cell-free and intracellular killing of NTS. These ﬁndings provide support for
antibody-based NTS vaccine development strategies, as they are likely to elicit both
extracellular and intracellular protection against iNTS. Neutrophil respiratory burst
constitutes a key mechanism of intracellular effector function for Salmonella killing (33).
Consistent with results of previous studies (16–18, 21), we have shown that NRBA with
respect to S. Typhimurium is reduced in both P. falciparum-infected and febrile malaria-
negative children compared to nonfebrile malaria-negative children. It has long been
known that P. falciparum infection-derived products, including heme, heme oxygenase,
and hemozoin, compromise neutrophil and monocyte effector functions in both hu-
mans and mice (16–18, 21, 34). In contrast to transient loss of serum killing with respect
to S. Typhimurium, we observed that both NRBA and WBBA were reduced for a period
longer than 30 days in malaria-convalescent children. This is in keeping with a previous
observation (18). Surprisingly, we found that NRBA was also reduced in febrile malaria-
negative children compared to nonfebrile malaria-negative children. How nonmalarial
febrile illness compromises the neutrophil respiratory burst is not clear. In this study, we
did not conﬁrm the etiology of nonmalarial febrile illnesses. Identifying the causes of
these febrile illnesses might provide insights into the mechanisms behind impaired
neutrophil respiratory burst. We recommend further investigations into the contribu-
tion of reduced C3 levels during the acute phase of malaria to poor NRBA and WBBA
with respect to S. Typhimurium, an aspect that was not explored in our current study.
These ﬁndings suggest that the loss of intracellular killing of NTS in P. falciparum-
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infected and nonmalarial febrile children is likely due to impaired neutrophil respiratory
burst activity.
Conclusion. We have demonstrated that P. falciparum infection transiently com-
promises humoral immunity to NTS in children, extending our knowledge of the
reasons that P. falciparum infection compromises cellular immunity to NTS. The results
of this study broaden our understanding of the immunologic basis of increased
susceptibility to iNTS during acute or convalescent malaria and of the epidemiological
association of malaria and iNTS in regions of malaria endemicity. The global immune
defects induced by P. falciparum infection may render children from regions of malaria
endemicity at risk of infections by not only iNTS but also other enteric Gram-negative
bacteria (35). Our study results further highlight the need to improve management of
concurrent malaria and IBIs, particularly by developing rapid diagnostic test for IBIs,
ideally to be run in parallel with rapid diagnostic tests for malaria. This could signiﬁ-
cantly improve the identiﬁcation of malaria and IBIs, promote rational prescribing of
antimicrobial agents, and improve health outcomes.
MATERIALS AND METHODS
Recruitment of study participants and follow-up. We recruited 154 children aged 6 to 60 months
at a Community Health Centre in Blantyre, Malawi, from January 2016 to August 2016. The study
participants comprised 59 febrile children presenting with uncomplicated malaria, 49 febrile malaria-
negative children, and 46 nonfebrile malaria-negative children (Table 1). P. falciparum-infected children
were followed up at day 14 (n  42) and day 30 (n  41) during convalescence. The uncomplicated-
malaria group was comprised of children with acute-phase P. falciparum infection who presented to the
hospital for medical care; they were febrile (37.8°C) at the time of recruitment, had positive malaria
rapid diagnostic test and positive malaria blood ﬁlm results, a Blantyre coma score of 5 (36), a
hemoglobin (Hb) level of 5 g/dl, and a serum glucose level of 45 mg/dl. Children with a positive HIV
antibody test result, severe anemia (Hb, 5 g/dl), malnutrition (weight-for-height Z-score, less than 2),
or other chronic illness were excluded from the study. A 3-ml venous blood sample was collected from
each participant at recruitment and during follow-up. Participants presenting with uncomplicated
malaria were treated according to Malawi Government guidelines, before blood sample collection.
Ethical approval for the study was obtained from the College of Medicine Research Ethics Committee
(protocol number P.08/15/1785), and written informed consent was obtained from parents or guardians
of participating children.
TABLE 1 Study participants’ demographic and clinical features
Parameter
Values
During malaria Nonmalarial controls
Acute (n  59) 2 wks (n  42) 1 mo (n  41)
Febrile
(n  49)
Nonfebrile
(n  46)
No. (%) of female participants 34 (58) 26 (62) 25 (61) 27 (55) 15 (39)
Median age in mo (range) 22.8 (6–59.8) 23.5 (6.6–60.2) 24.1 (7–61) 22.8 (6–59.3) 21.9 (6.7–50.7)
Median wt in kg (range) 10.2 (6.9–17) 10.5 (7 16.1) 10.1 (7.1–16.3) 10.1 (6.9–15.4) 10.5 (7.1–15.5)
Median ht in cm (range) 84 (66–113) 85 (75–113) 85 (75.6–113) 84.5 (74–104) 82.5 (64–106)
Median MUACa in cm (range) 14 (10.2–19) 13.8 (10–18.7) 13.95 (10.4–18.8) 13.4 (10–16.2) 14.2 (10.2–17.5)
Median Hb level in g/dl (range) 9.5 (5.9–12.3) 9.7 (7.3–12.4) 10.3 (8.4–12.7) 10.8 (7.9–18.7) 11 (5.2–13.6)
Median absolute no. of lymphocytes  103/l (range) 3.4 (0.9–9.8) 5.3 (2.2–9.2) 5.3 (1.7–15.2) 4.2 (1.2–14.9) 5.4 (2.2–69.2)
Median absolute no. of neutrophils  103/l (range) 3.7 (0.93–11.4) 2.8 (1.2–3.9) 2.8 (0.5–5.9) 3.6 (0.2–19.9) 2.3 (0.18–22.2)
No. (%) of subjects with:
Splenomegaly 20 (39) 1 (2.4) 0 (0) 4 (8.2) 1 (2.6)
Cough 24 (40.6) 9 (21.4) 9 (22) 29 (59) 0 (0)
Shortness of breath 1 (1.7) 0 (0) 0 (0) 13 (26.5) 0 (0)
Vomit 21 (35.6) 1 (2.4) 2 (4.9) 25 (51) 0 (0)
Diarrhea 14 (23.7) 0 (0) 2 (4.9) 14 (28.6) 0 (0)
aMUAC, mid-upper arm circumference.
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Quantiﬁcation of S. Typhimurium-speciﬁc SBA. Serum bactericidal activity (SBA) assays were
performed as previously described (23). Brieﬂy, serum or phosphate-buffered saline (PBS) was mixed with
S. Typhimurium D23580 (37), adjusted to 1.0  106 CFU/ml, and incubated at 37°C for 180 min. Test
samples were serially diluted and plated in triplicate on Luria Bertani agar. Colony counts of S.
Typhimurium were done after 24 h of incubation. Log10 changes in S. Typhimurium CFU counts per
milliliter from the baseline were reported.
Quantiﬁcation of S. Typhimurium-speciﬁc whole-blood-cell and washed-blood-cell killing.
Three conditions were prepared as previously described (24). For condition 1, whole blood was used in
a whole-blood bactericidal assay (WBBA). For condition 2, whole blood was washed twice with RPMI 1640
at 1,000 rpm for 10 min before being used in a washed-blood-cell bactericidal assay (WBCBA). For
condition 3, S. Typhimurium adjusted to 1.0 107 CFU/ml was ﬁrst opsonized with 1:10 serum from each
participating child for 20 min at room temperature (RT) before challenging washed blood cells in a
washed-blood-cell and serum-opsonized assay (WBCSOA). All conditions were challenged with S. Typhi-
murium adjusted to a ﬁnal concentration of 1.0  107 CFU/ml. Colony counts were performed as
described for the SBA experiment above.
Quantiﬁcation of anti-S. Typhimurium IgG antibody titer by ELISA. These experiments were
performed as previously described (25). Brieﬂy, enzyme-linked immunosorbent assay (ELISA) plates
(Nunc-Immuno) were coated overnight with 100 l of carbonate-bicarbonate buffer (Sigma-Aldrich) per
well containing 7.5 g/ml S. Typhimurium LPS antigen (Alexis Biochemicals). Plates were washed with
PBS containing 0.05% Tween 20 and blocked with 200 l/well blocking buffer (PBS–1% bovine serum
albumin [BSA]) for 1 h at 37°C. Test serum prepared at 1:20 in dilution buffer (PBS–0.05% Tween 20–1%
BSA) was serially diluted 3-fold and incubated at 37°C for 1 h. After washing, 100 l of 1:2,000 secondary
goat anti-human IgG-AP antibodies (Southern Biotech) was added and incubated for 1 h at 37°C. Finally,
after washing, 100 l of SigmaFAST p-nitrophenyl phosphate substrate was added to each plate and the
plate was read after 30 min using a BioTek ELx800 reader (BioTek Instruments, USA) at 405 nm.
Quantiﬁcation of complement components binding on the surface of S. Typhimurium. These
experiments were performed as previously described (23, 28). A 5-l volume of S. Typhimurium was
gently mixed at 2 108 CFU/ml with 45 l of undiluted serum or PBS (control) at RT for 20 min. Samples
were washed twice with 1 ml PBS by spinning for 5 min at 3,300  g. A 2-l volume of anti-C3c
ﬂuorescein isothiocyanate (FITC)-conjugated antibody (Abcam) was added to 50 l of pellet to measure
C3 deposition. A 1-l volume of anti-C5b-9 neo-epitope antibody (Abcam) and 2 l of rabbit anti-mouse
FITC-conjugated antibody (Abcam) were added to 50 l of pellet to measure MAC levels. Samples were
washed twice with 1 ml of PBS after 20 min of incubation at RT and ﬁxed with 200 l of 1%
formaldehyde–PBS. Samples were acquired on a CyAN ADP ﬂow cytometer (Beckman Coulter) and
analyzed using Flow Jo version 7.6.5.
Quantiﬁcation of neutrophil respiratory burst. A Phagoburst test kit (Glycotope Biotechnology)
was modiﬁed to measure neutrophil respiratory burst levels as previously described (24). Whole blood
(45 l) was incubated on ice for 10 min and then stimulated with serum-opsonized S. Typhimurium at
1.0  108 CFU/ml or with a wash solution containing instalmed-salts (control). Samples were then
incubated for 10 min at 37°C to allow phagocytosis followed by 10 min of incubation at 37°C after
addition of dihydrorhodamine 123 to promote oxidation. The reaction was stopped by application of
1:10 lysing solution for 20 min at RT. Samples were acquired on CyAN ADP ﬂow cytometer (Beckman
Coulter) and analyzed using Flow Jo version 7.6.5.
Statistical analyses. Statistical analyses were performed using GraphPad Prism version 5 (GraphPad
Software, USA). Log10 change in bactericidal activity with respect to S. Typhimurium, percentage of
neutrophil respiratory burst-positive cells, and complement deposition were examined for normality of
distribution using the D’Agostino and Pearson omnibus normality test. Nonparametric data were
compared using the Mann-Whitney U test or the Wilcoxon signed-rank test for paired t tests. Median and
interquartile range (IQR) were reported, and a P value of less than 0.05 was considered statistically
signiﬁcant. Spearman’s correlation coefﬁcient r was used to determine relationships between bactericidal
activity and age and anti-S. Typhimurium LPS IgG antibody titers during malaria.
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